CIBUS INC Stock Price, News & Analysis

Cibus (NASDAQ:CBUS) reported Q2 2025 financial results and provided significant business updates. The company is streamlining operations to focus on Rice herbicide tolerance traits and partner-funded programs, aiming to reduce annual cash usage to $30 million by 2026.

Key developments include: commercialization of Rice herbicide tolerance traits HT1 and HT3 targeting Latin America launch in 2027 and U.S. expansion in 2028, with potential annual royalties exceeding $200 million; a new collaboration with Colombian Rice producer Semillano; and progress in sustainable ingredients programs expected to generate initial revenues in 2025.

Financial highlights: Q2 net loss of $26.6 million ($0.61 per share), cash position of $36.5 million, and successful completion of a $27.5 million public offering. The company expects current cash to fund operations into Q2 2026.

Cibus (Nasdaq: CBUS), an agricultural technology company specializing in plant trait development and licensing, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET the same day. Investors can access the call using U.S. dial-in (+1-833-316-2483) or International dial-in (+1-785-838-9284) with conference ID "CIBUS" or 24287. A replay will be available until August 28, 2025. The webcast and slides will be accessible through the investor section of Cibus' website for 90 days after the event.

Cibus (NASDAQ:CBUS), an agricultural technology company, announced a reduction in force (RIF) as part of implementing its streamlined business strategy. The company will focus on its nearest-term revenue opportunities, particularly in rice weed management traits and biofragrance products.

The restructuring will incur one-time charges of approximately $0.5 million in Q3 2025. Through these initiatives, Cibus aims to reduce its annual net cash usage to approximately $30 million by 2026. The company will prioritize its Trait Machine™ gene editing processes for HT1, HT3, and other trait combinations while maintaining customer-funded crop-based sustainable ingredients programs.

Cibus (NASDAQ: CBUS) has successfully completed the FDA's Plant Biotechnology Consultation Program for its altered lignin alfalfa trait, developed in partnership with S&W Seed Company. The FDA confirmed it has no further questions regarding the use of this gene-edited alfalfa in food or feed applications.

The altered lignin alfalfa offers two key benefits: potential improved digestibility for livestock and greater harvest timing flexibility for farmers. S&W Seed Company plans to commercialize two initial variety offerings - a fall dormancy five variety and a fall dormancy seven variety - marking the first commercial gene-edited alfalfa varieties in the United States.

Cibus (CBUS) announced an ongoing collaboration with the John Innes Centre (JIC) to develop a groundbreaking nutrient use efficiency (NUE) trait for commercial crops. The partnership builds on JIC's discovery of a genetic mutation that enhances plant-microbe interactions for improved nutrient uptake, potentially reducing fertilizer requirements without impacting yields. The collaboration focuses on translating this discovery into traits for various crops, with Cibus already reporting successful editing of Canola plants. The development is particularly significant as typically only one-third of applied fertilizer is absorbed by plants, making this innovation potentially transformative for sustainable and profitable farming practices.

Cibus (NASDAQ: CBUS), a leading agricultural biotechnology company, has completed its previously announced public offering, raising $27.5 million through the sale of 15,714,285 shares of Class A Common Stock at $1.75 per share. Notable participants included institutional and strategic investors, with the Chairman of Cibus' board of directors purchasing 5,714,286 shares. A.G.P./Alliance Global Partners served as the sole placement agent. The company plans to utilize the net proceeds to advance the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. The offering was conducted under an effective shelf registration statement filed with the SEC.

Cibus (NASDAQ: CBUS) announced that its herbicide tolerance trait (HT2) in Canola has received a 'not regulated' designation from the USDA-APHIS Biotechnology Regulatory Services. This marks Cibus' 17th trait to receive this designation, following recent approval of their disease resistance traits in Canola. The HT2 trait, developed using Cibus' Rapid Trait Development System (RTDS), aims to provide farmers with advanced weed management solutions, particularly targeting weeds resistant to commonly-used herbicides. The technology is especially significant for broad acre crops like Canola and Soybean, where weed control directly impacts crop yields. This regulatory milestone reinforces Cibus' momentum in both U.S. and international markets as they continue developing productivity and agronomic traits.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company, has announced the pricing of a public offering of 15,714,285 shares of Class A Common Stock at $1.75 per share, aiming to raise approximately $27.5 million in gross proceeds. The offering includes participation from institutional and strategic investors, with the Chairman of Cibus' board of directors purchasing 5,714,286 shares. The company plans to use the proceeds to fund the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. A.G.P./Alliance Global Partners is serving as the sole placement agent, with the offering expected to close around June 6, 2025.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in gene editing for plant traits in seeds, has announced a proposed public offering of Class A common stock. The company's board chairman, Rory Riggs, has expressed interest in purchasing up to $10 million of shares, though this is not a binding commitment. A.G.P./Alliance Global Partners will serve as the sole placement agent. The net proceeds will be used to fund the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. The offering will be made under an effective shelf registration statement filed with the SEC in June 2023.